Akèy › Kansè san › Nebraska › Omaha
Etid klinik pou Kansè san nan Omaha, NE
10 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote Omaha (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Ap rekriteEtid obsèvasyon
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi lwen
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- The University of Nebraska Medical Center, Omaha
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- University of Nebraska Medical Center, Omaha
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Ap rekriteFaz 1
- University of Nebraska Medical Center, Omaha
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- University of Nebraska Medical Center, Omaha
Halt Aging in Survivors of Blood Cancers
Ap rekrite
- University of Nebraska Medical Center, Omaha
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Ap rekriteFaz 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Fred and Pamela Buffett Cancer Center, Omaha
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Ap rekriteFaz 2
- University of Nebraska Medical Center, Omaha
Etid Kansè san nan lòt vil
- Houston, TX46 etid
- New York City, NY26 etid
- Boston, MA25 etid
- Washington, DC19 etid
- Baltimore, MD18 etid
- Seattle, WA18 etid
- Los Angeles, CA17 etid
- Durham, NC16 etid
- Chicago, IL15 etid
- Philadelphia, PA14 etid
- Atlanta, GA13 etid
- Nashville, TN13 etid
Lòt etid nan Omaha
- Kansè pwostat27 etid
- Kansè Poumon ki pa ti selil24 etid
- Kansè nan tete22 etid
- Kansè kolorektal18 etid
- Kansè (tout kalite)18 etid
- Myelom Miltip16 etid
- Limfòm Non-Hodgkin14 etid
- Kansè ovè14 etid
- Kansè pankreyas14 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
- Ensifizyans kadyak13 etid
- Kansè Metastatik13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.